International Journal of Advanced Community Medicine

E-ISSN: 2616-3594
P-ISSN: 2616-3586
Impact Factor (RJIF): 5.89
www.comedjournal.com
IJACM 2025; 8(4): 15-20
Received: 14-08-2025
Accepted: 19-09-2025

Dr. Rohit Deoli
Master of Public Health (MPH) Scholar, Department of Community Medicine, (AIIMS), Rishikesh, Uttarakhand, India

Dr. Ravi Kumar
Deputy Medical Superintendent, (AIIMS), Rishikesh, Uttarakhand, India

Dr. Shikha Thakur
Master of Public Health (MPH) Scholar, Department of Community Medicine, (AIIMS), Rishikesh, Uttarakhand, India

Dr. Sewapreet Singh Gill
MD Community Medicine, AIIMS Rishikesh, Uttarakhand, India

Dr. Aakash Sachadeva
MD Community Medicine, AIIMS Rishikesh, Uttarakhand, India

Dr. Rajesh Kumar
Professor Department of Biomedicine, NIHFW New Delhi, India

Corresponding Author:
Dr. Rohit Deoli
Master of Public Health (MPH) Scholar, Department of Community Medicine, (AIIMS), Rishikesh, Uttarakhand, India

India's pillars of trust: CDSCO's role in drug development and quality assurance

Rohit Deoli, Ravi Kumar, Shikha Thakur, Sewapreet Singh Gill, Aakash Sachadeva and Rajesh Kumar

DOI: https://www.doi.org/10.33545/comed.2025.v8.i4.A.422

Abstract
India's pharmaceutical industry is a global beacon, delivering affordable medicines under the watchful eye of the Central Drugs Standard Control Organization (CDSCO). This narrative review dives into CDSCO's world, exploring its structure, workforce, testing labs, licensing, certifications, exports, and challenges. Drawing from CDSCO reports, government documents, and recent analyses (2024-2025), it traces milestones like the 2019 New Drug and Clinical Trial (NDCT) Rules, 2024 Uniform Code of Pharmaceutical Marketing Practices (UCPMP), and 2025 biosimilars updates, showcasing India's alignment with global standards. Despite strides, reliance on Chinese APIs poses risks. Recommendations include AI-driven monitoring, expanding local API production, and fostering partnerships to strengthen CDSCO's mission, ensuring India remains a trusted pharma powerhouse for safe, effective care.

Aims: This review explores CDSCOs structure, functions, workforce, testing labs, licensing, certifications, exports, and challenges, emphasizing its role in drug development and quality assurance, with a focus on 2024-2025 updates like biosimilars guidelines and the Uniform Code of Pharmaceutical Marketing Practices (UCPMP).

Methods: This narrative review synthesizes insights from recent government reports, peer-reviewed journals, news outlets, and industry platforms, credible sources were synthesized, covering regulatory policy, pharmacovigilance, and API dependence, with cross-verification for accuracy in a narrative review format.

Results: CDSCOs robust regulatory framework, supported by zonal and port offices, enforces good manufacturing practices and expands pharmacovigilance and testing infrastructure, aligning with global standards. However, reliance on Chinese APIs remains a challenge. Recommendations include AI-driven monitoring and local API production to strengthen Indias global pharmaceutical leadership.

Keywords: API dependence, biosimilars, CDSCO, complaint portal, drug advertisement regulation, drug regulation, drug testing labs, exports, global standards, GMP, ICH, Indian Pharmacopoeia, licensing, medical devices, NDCT, ONDLS, pharmaceutical industry, pharmacovigilance, PLI, public awareness PvPI quality assurance regulatory challenges SUGAM, UCPMP, WHO

1. Introduction

Imagine stepping into a bustling Indian market, where stalls overflow with life-saving medicines and sleek medical devices. At the heart of this vibrant scene stands the Central Drugs Standard Control Organization (CDSCO), ensuring every product is safe, effective, and trustworthy [1]. Nestled under the Ministry of Health and Family Welfare, CDSCO's mission is to keep this marketplace thriving, covering everything from simple bandages to high-tech diagnostics, as laid out in the Drugs and Cosmetics Act of 1940 and its 1945 Rules [2].

This story began in colonial times, when substandard imported drugs raised alarms, birthing the 1940 Act. Since CDSCO's launch in 1940, it's been a steady force for change [2]. Think of its milestones as stepping stones: Good Manufacturing Practices (GMP) in 1988, crackdowns on fake drugs in 2008 (with penalties like life imprisonment), and the 2019 New Drugs and Clinical Trials Rules (NDCT) that put ethics first while speeding up approvals [3, 4, 14]. The 2017 Medical Devices Rules brought clarity to a complex field, while recently moves the harmonized Indian Pharmacopoeia (IP 2022), the binding 2024 Uniform Code for Pharmaceutical Marketing Practices (UCPMP), and 2025 biosimilars guidelines, show India striding alongside global leaders like the International Council for Harmonisation (ICH) and

World Health Organization (WHO) [5, 6, 7]. Digital platforms like SUGAM and ONDLS are like trusty sidekicks, streamlining processes, while new labs in Bihar (2025's Agam Kuan) and Uttar Pradesh's planned 12-division rollout by July 2025 are game-changers, cutting delays and boosting local expertise [8, 9]. As the world's third-largest pharma hub by volume, India juggles affordability and quality, but dependence on Chinese active pharmaceutical ingredients (APIs) is a nagging worry [11].

2. Methods

This narrative review synthesizes insights from recent sources searched and selected for relevance and credibility. Sources were identified through targeted searches on government websites (e.g., CDSCO, Ministry of Health and Family Welfare), academic databases for peer-reviewed journals (e.g., via PubMed, LWW), news outlets (e.g., Times of India, New Indian Express), industry reports (e.g., PharmaBiz, Grand View Research), and specialized platforms (e.g., Drug Patent Watch, USIP). Inclusion criteria focused on materials from 2024-2025 to capture the latest developments, alongside foundational documents from earlier years for historical context. Domains covered include regulatory policy (e.g., NDCT Rules, Medical Devices Rules), pharmacovigilance and quality assurance, export and licensing procedures, human resources and training, laboratory infrastructure, and strategic challenges like API dependence. No rigid systematic protocol was followed, aligning with the exploratory nature of narrative reviews, but sources were cross-verified for accuracy and bias to paint a comprehensive picture of CDSCOs regulatory journey.

3. Organizational Structure of CDSCO

Picture CDSCO as a mighty banyan tree, its roots in New Delhi and branches stretching across India. Leading the charge is the Drugs Controller General of India (DCGI), Dr. Rajeev Singh Raghuvanshi, from the bustling FDA Bhawan [12]. Headquarters is the nerve centre, with teams tackling new drugs, clinical trials, medical devices, pharmacovigilance, cosmetics, blood products, and tech-savvy quality systems. A new Coordination Division, launched in April 2025, handles the grunt work, like monthly Cabinet reports allowing the team to focus on eliminating fake medicines and improving inspections [10].

CDSCO's reach spans nine zonal offices (Ghaziabad, Chennai, Mumbai-1, Mumbai-2, Kolkata, Hyderabad, Ahmedabad, Bangalore, Baddi), seven sub-zonal offices (Varanasi, Goa, Jammu, Indore, Guwahati, Visakhapatnam, Rishikesh), and 18 port offices at hubs like Chennai, Kolkata, Mumbai, Delhi, and beyond [12]. These outposts keep imports and exports honest, backed by a dedicated crew: Deputy Drugs Controllers (DDC [I]), Assistant Drugs Controllers (ADC [I]), Drug Inspectors (DI), and support staff [12]. Seven central labs are the quiet heroes: CDL Kolkata handles appeals, CDTLs in Mumbai, Hyderabad, and Chennai test quality, RDTLs in Guwahati and Chandigarh support regions, and CDL Kasauli dives into biologics and vaccines [13]. Port mini labs act like swift sentinels, screening imports on the spot. Hand in hand with State Licensing Authorities (SLAs), CDSCO's a well-tuned orchestra, blending national oversight with local grit [10].

3.2 Roles and Responsibilities of CDSCO

CDSCO's got its hands full, from greenlighting new drugs and trials under the 2019 NDCT Rules (with a 2024 nudge for CRO registration) to setting gold standards through the Indian Pharmacopoeia Commission (IPC) [14, 15]. The IP 2022 edition holds its own against global giants like USP [6]. CDSCO ensures states follow the Drugs and Cosmetics Act, keeping a sharp eye on blood derivatives and vaccines [3].

Quality is CDSCO's guiding light. It enforces GMP under Schedule M, with a 2025 mandate for manufacturers to track side effects via pharmacovigilance [16]. The Pharmacovigilance Programme of India (PvPI), with 250+ centres, is like a nationwide safety net [16]. Biosimilars face tough 2025 guidelines aligned with ICH Q1A [7]. Medical devices are sorted into four risk tiers—Class A (think thermometers), B (infusion pumps), C (ventilators), and D (pacemakers), under 2017 Rules, needing robust quality systems and 2025 sterilization standards [5, 19]. Labels now sport Unique Device Identification (UDI) since 2022 and excipient details since 2024, making everything traceable [16]. Inspections, seizures, and UCPMP 2024 rules banning perks like doctor trips keep the industry on the straight and narrow [16].



Fig 1: ORGANOGRAM OF CDSCO [1]

3.3 Human Resources
CDSCO's team is like a close-knit band: the DCGI leads the melody, Joint Drug Controllers (JDC[I]) write the score, Deputy/Assistant Drug Controllers keep the beat, Drug Inspectors pound the pavement, Technical Data Associates crunch the numbers, and lab staff fine-tune the science [20]. Training with NIHFW, NIPER, IPC, WHO, and USFDA hones skills in GMP, Good Clinical Practices (GCP), and biologics/devices [20]. States like Bihar and Uttar Pradesh are bolstering teams with microbiologists and chemists through PM-ABHIM, filling gaps and sharpening local know-how [21].

3.4 Status of Drug Testing Bodies
CDSCO's labs are the gold standard: CDL Kolkata tackles appeals, CDTLs in Mumbai, Chennai, and Hyderabad test quality, RDTLs in Guwahati and Chandigarh cover regions, and CDL Kasauli specializes in biologics/vaccines, all aligned with IP 2022 and ICH [13]. Port mini labs are like quick-draw sheriffs, screening imports fast. States stepped up with 17 new labs and 24 upgrades in 2024-2025, tied to SUGAM [22]. Bihar's 2025 Agam kuan lab, with 28 high-tech tools, and Uttar Pradesh's 12-division plan by July 2025 are slashing delays [8, 9]. Gujarat's Surat lab got a Rs 32 crore boost, and Maharashtra's mobile units are on the move [24]. The 2025 SHRESTH index spurs states to shine [25].

3.5 System of Licensing and Accreditation in CDSCO
Licensing is divided between the Central Licensing Authority (CLA) for high-risk items (Class C/D devices, imports, clinical trials) using Forms MD-3 to MD-10, and State Licensing Authorities (SLAs) for low-risk items (Classes A/B) and sales [14, 26]. Digital platforms SUGAM and ONDLS streamline applications; audits are required for Class B-D devices, though products approved in the US, EU, or Japan may bypass trials with a free sale certificate [26]. Laboratories require NABL accreditation, GMP certificates renewed every five years, and quality management systems, with pharmacovigilance mandatory from 2025 [16, 26]. Updates in 2025 include excipient labelling and compounding regulations for transparency [18].

3.6 Activities Related to Certification and Drug Seizure
GMP and Certificate of Pharmaceutical Product (CoPP) certifications facilitate exports, alongside free sale certificates for imports [27]. In 2025, CDSCO simplified No Objection Certificates (NOCs) for established firms and introduced guidelines for disposing expired drugs [17]. Seizures address counterfeit (Category A), substandard (Category B), and minor-defect (Category C) drugs, with over 3, 000 substandard samples identified in 2024-2025 resulting in license suspensions [23, 41].

3.7 Export of Drugs and Various Ports from India
Exports need CoPP and GMP, with 2025 reforms easing NOCs for reliable players [27]. Eighteen ports, Chennai, Mumbai, Delhi, and more handle clearances, with port labs ensuring quality [12]. A Rs 100 crore digital push in 2024-25 keeps exports flowing smoothly [16].

3.8 Policies and Strategic Challenges
Recent policies include 2025 updates to the Drugs and Cosmetics Act on excipients and compounding, NDCT Rules amendments for CRO registration, and pharmacovigilance guidelines [14, 16, 18]. The 2024 UCPMP prohibits unethical marketing practices, such as incentives to physicians [16]. Indias 70-80% dependence on Chinese APIs poses supply chain risks [28, 29]. CDSCO is addressing this through Production Linked Incentive (PLI) schemes, import diversification, the India-US TRUST initiative, and development of API parks [30, 32, 33].

4. Conclusion
CDSCO is India's rock, holding up a pharma industry that saves lives worldwide. Its sprawling network, nine zonal offices, seven sub-zonal offices, 18 ports, and seven labs, works tirelessly to ensure drugs and devices are safe [12, 13]. From the IP 2022's global alignment to UCPMP 2024's ethical crackdown and 2025 biosimilars rules, CDSCO's keeping pace with ICH and WHO [6, 7, 16]. But the shadow of Chinese API reliance looms large [28]. The path forward? Embrace AI for real-time safety checks, expand PLI schemes to grow local APIs, and keep industry talks alive through partnerships [25, 30, 35]. More training hubs, like those in Bihar and Uttar Pradesh, will empower teams [21]. Streamlining approvals and global trial waivers can ignite innovation [34]. Awareness to public on CDSCO activities and direct complaint portal for public, regulations towards drug related advertisement in mass media is one of the important steps for regulation of drugs in India. With these steps, CDSCO can cement India's place as a global pharma leader, delivering trust in every dose.

Conflict of Interest
The author declares no conflicts of interest. This review was conducted independently, with no financial or personal relationships that could influence the objectivity of the findings or recommendations presented.

Acknowledgement
This narrative review was carried out during my internship at the National Institute of Health and Family Welfare (NIHFW), New Delhi, from 1st July 2025 to 31st July 2025. I, Dr. Rohit Deoli, am deeply grateful to my supervisor, Prof. Rajesh Kumar, Nodal Officer (Admin), and Dr. Ravi Kumar, DMS, AIIMS Rishikesh, for their valuable guidance, constructive feedback, and constant encouragement, which significantly enhanced the quality and clarity of this work.
I also express my sincere gratitude to the institute for providing the opportunity, academic resources, and a supportive environment necessary to successfully complete this study.

References
1. Central Drugs Standard Control Organization. Introduction [Internet]. New Delhi: CDSCO; 2025 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/en/About-us/Introduction/
2. Ministry of Health and Family Welfare. The Drugs and Cosmetics Act, 1940 and Rules, 1945. New Delhi: Government of India; 2016.
3. Central Drugs Standard Control Organization. Functions [Internet]. New Delhi: CDSCO; 2025 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/en/About-us/Functions/
4. Central Drugs Standard Control Organization. Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2016. New Delhi: CDSCO; 2016.
5. Ministry of Health and Family Welfare. Medical Devices Rules, 2017. New Delhi: Government of India;

2017.
6. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. Ghaziabad: IPC; 2022.
7. Central Drugs Standard Control Organization. Revised Guidelines on Similar Biologics - Regulatory Requirements for Marketing Authorization in India, 2025 [Internet]. New Delhi: CDSCO; 2025 May 6 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf%20documents/DgSimilaBiologics25.pdf
8. Times of India. Advanced facility launched to test drugs & food locally [Internet]. 2025 Jun 27 [cited 2025 Aug 18]. Available from: Advanced facility launched to test drugs & food locally - Times of India.pdf
9. Times of India. Modern food & drug testing labs in 12 divs [Internet]. 2025 May 11 [cited 2025 Aug 18]. Available from: Modern food & drug testing labs in 12 divs - Times of India.pdf
10. Central Drugs Standard Control Organization. Organization Structure [Internet]. New Delhi: CDSCO; 2025 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/en/About-us/Organization-Structure/
11. DrugPatentWatch. Indian Pharmaceutical Industry: Navigating Challenges and Acceptances [Internet]. 2025 [cited 2025 Aug 18]. Available from: https://www.drugpatentwatch.com/blog/indian-pharma-some-challenges-and-acceptances/
12. Central Drugs Standard Control Organization. Organogram [Internet]. New Delhi: CDSCO; 2025 [cited 2025 Aug 18]. Available from: organogram.pdf
13. Central Drugs Standard Control Organization. Laboratories [Internet]. New Delhi: CDSCO; 2025 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/en/About-us/Laboratories/
14. Ministry of Health and Family Welfare. The New Drugs and Clinical Trials Rules, 2019. New Delhi: Government of India; 2019.
15. Central Drugs Standard Control Organization. New Drugs and Clinical Trials (Amendment) Rules, 2024 [Internet]. New Delhi: CDSCO; 2024 Sep 19 [cited 2025 Aug 18]. Available from: THE NEW DRUGS AND CLINICAL TRIALS RULES, 2019.pdf
16. Indian Pharmacopoeia Commission. Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products. Ghaziabad: IPC-CDSCO; 2024.
17. Central Drugs Standard Control Organization. Public Notice on Disposal of Expired/Unused Drugs [Internet]. New Delhi: CDSCO; 2025 May 27 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTI3NTI=
18. Central Drugs Standard Control Organization. Gazette Notification G.S.R. 345(E) [Internet]. New Delhi: CDSCO; 2025 May 28 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/
19. Central Drugs Standard Control Organization. Regulatory Requirements for Outsourcing Sterilization Activity of Medical Devices [Internet]. New Delhi: CDSCO; 2025 Jun 24 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTI4NDk=
20. Central Drugs Standard Control Organization. Human Resources and Training [Internet]. New Delhi: CDSCO; 2025 [cited 2025 Aug 18]. Available from: common national guidelines followed in states.pptx
21. Ministry of Health and Family Welfare. Status of Drug Quality Testing under CDSCO [Internet]. New Delhi: MoHFW; 2025 Apr 2 [cited 2025 Aug 18]. Available from: https://www.mohfw.gov.in/?q=en/pressrelease/status-drug-quality-testing-under-cdsco
22. Healthcare Asia Magazine. India launches index to benchmark state drug regulatory systems [Internet]. 2025 Aug 14 [cited 2025 Aug 18]. Available from: https://healthcareasiamagazine.com/healthcare/news/india-launches-index-benchmark-state-drug-regulatory-systems
23. New Indian Express. Over 3K drug samples declared not of standard quality in 2024-25 [Internet]. 2025 Jul 22 [cited 2025 Aug 18]. Available from: https://www.newindianexpress.com/nation/2025/Jul/22/over-3k-drug-samples-declared-not-of-standard-quality-in-2024-25-union-health-minister-jp-nadda
24. PharmaBiz. Gujarat FDCA receives Rs. 32 crore from state govt to expand Surat drug testing lab [Internet]. 2025 Aug 14 [cited 2025 Aug 18]. Available from: https://www.pharmabiz.com/NewsDetails.aspx?aid=180698&sid=1
25. Press Information Bureau. SHRESTH - State Health Regulatory Excellence Index [Internet]. 2025 Aug 12 [cited 2025 Aug 18]. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2155722
26. Central Drugs Standard Control Organization. Medical Devices Rules, 2017 [Internet]. New Delhi: CDSCO; 2017 [cited 2025 Aug 18]. Available from: Medical Devices Rules, 2017.pdf
27. Central Drugs Standard Control Organization. Revised Export NOC Guidance [Internet]. New Delhi: CDSCO; 2025 Jul 17 [cited 2025 Aug 18]. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTI5MjM=
28. TaxTMI. Challenges Faced by India's Pharmaceutical Industry [Internet]. 2025 Apr 2 [cited 2025 Aug 18]. Available from: https://www.taxtmi.com/article/detailed?id=13991
29. USIP. How vulnerable is India to Chinese economic coercion? [Internet]. 2025 Jun 16 [cited 2025 Aug 18]. Available from: https://www.usip.org/publications/2025/06/how-vulnerable-india-chinese-economic-coercion
30. BW Healthcare World. API dependence & India's path to self-reliance in complex drug manufacturing [Internet]. 2025 Apr 24 [cited 2025 Aug 18]. Available from: https://www.bwhealthcareworld.com/article/api-dependence-indias-path-to-self-reliance-in-complex-drug-manufacturing-554815
31. LinkedIn. India's pharma industry emerges as a growing challenge for China [Internet]. 2025 Jun 26 [cited 2025 Aug 18]. Available from: https://www.linkedin.com/pulse/indias-pharma-industry-emerges-growing-challenge-china-dfmhf/
32. Carnegie Endowment. The India-U.S. TRUST Initiative: A resilient pharma supply chain [Internet]. 2025 Apr 23 [cited 2025 Aug 18]. Available from:

https://carnegieendowment.org/posts/2025/04/india-us-trust-initiative-a-resilient-pharma-supply-chain?lang=en
33. LGM Pharma. Tariffs and geopolitics: API supply chain resilience in 2025 [Internet]. 2025 Feb 25 [cited 2025 Aug 18]. Available from: https://lgmpharma.com/blog/tariffs-api-supply-chain-resilience-in-2025/
34. LWW. Generic giants to biotech frontiers: mapping India's pharma. Med Gas Res [Internet]. 2025 [cited 2025 Aug 18]. Available from: https://journals.lww.com/mgmj/fulltext/2025/04000/generic_giants_to_biotech_frontiers__mapping.23.aspx
35. Central Drugs Standard Control Organization. CDSCO seeks urgent industry inputs on regulatory challenges and innovation in pharma [Internet]. 2025 Jan 23 [cited 2025 Aug 18]. Available from: https://www.pharmabiz.com/NewsDetails.aspx?aid=174849&sid=1
36. Nishith Desai. Medical research in India [Internet]. 2025 Jan 21 [cited 2025 Aug 18]. Available from: https://nishithdesai.com/generateHTML/15241/4
37. Food Research Lab. CDSCO 2025: Cosmetic vs drug borderline guidelines India [Internet]. 2025 May 14 [cited 2025 Aug 18]. Available from: https://www.foodresearchlab.com/insights/regulation-updates/cdsco-guidelines-2025/
38. Trial MedPath. India's CDSCO releases draft guidelines for biosimilars approval [Internet]. 2025 May 19 [cited 2025 Aug 18]. Available from: https://trial.medpath.com/news/24f85b1f4714ef00/india-s-cdsco-releases-draft-guidelines-for-biosimilars-approval-with-focus-on-advanced-analytical-methods
39. Company Connects. India's evolving drug regulatory landscape: CDSCO updates [Internet]. 2025 Mar 29 [cited 2025 Aug 18]. Available from: https://www.companysconnects.com/post/india-s-evolving-drug-regulatory-landscape-cdsco-updates
40. ClinRegs. Clinical research regulation for India [Internet]. 2025 [cited 2025 Aug 18]. Available from: https://clinregs.niaid.nih.gov/country/india
41. The Health Master. Drug-Alert-February-2025-States [Internet]. 2025 Mar [cited 2025 Aug 18]. Available from: https://thehealthmaster.com/wp-content/uploads/2025/03/Drug-Alert-February-2025-States.pdf
42. Grand View Research. India drug testing market size & outlook, 2024-2030 [Internet]. 2025 [cited 2025 Aug 18]. Available from: https://www.grandviewresearch.com/horizon/outlook/drug-testing-market/india
43. Chemzin Biotox. Top #1 drug testing labs in India [Internet]. 2025 [cited 2025 Aug 18]. Available from: https://www.chemzinbiotox.com/drug-testing-labs-in-india/

How to Cite This Article
Deoli R, Kumar R, Thakur S, Gill SS, Sachadeva A, Kumar R. India's pillars of trust: CDSCO's role in drug development and quality assurance. International Journal of Advanced Community Medicine 2025; 8(4): 15-20.